Stocks · News reference
aTyr Pharma Q2 EPS $(0.11) Beats $(0.12) Estimate
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 50 percent increase over losses of $(0.22) per share from the same
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 8:02 PM
- Checked
- Aug 7, 2026, 8:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
aTyr Pharma CFO Jill Broadfoot To Step Down As Of September 30; To Be Succeeded By Brandon Yaras As Of October 1
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase
Read original at benzingaaTyr Pharma CFO Jill Broadfoot To Step Down Sept. 30, 2026
Read original at benzingaaTyr Pharma Reduces Workforce By ~60%
Read original at benzinga